R. David Yost retired with $568 million to “spend time with family” and was never held accountable.

The Opioid CEO Nobody Knows

By Northpoint Research

806,000 Americans are dead.

That’s the official CDC count of opioid overdose deaths in the United States between 1999 and 2023. It is larger than the U.S. death toll in World War II. It is larger than the combined U.S. death toll of every war America has fought since Korea. It happened here, at home, one family at a time, over two and a half decades.

You know the Sacklers. Their name was removed from the Metropolitan Museum of Art, from the Louvre, from the Tate Modern. Patrick Radden Keefe wrote a book about them. Hulu made a miniseries. Congressional hearings. Civil suits. Criminal referrals. The family that made the pills has been the face of American accountability — or the face of its absence — for years.

But the pills didn’t walk into pharmacies. They moved through a supply chain. Three companies controlled most of it. One of those companies was AmerisourceBergen.

The man who ran AmerisourceBergen for fourteen years has never been the subject of a documentary, a congressional hearing, or a single published interview about the opioid crisis. He has a plaza named after him at the United States Air Force Academy. His name is R. David Yost.

Who He Is

R. David “Dave” Yost served as Chief Executive Officer of AmerisourceBergen Corporation from 1997 to 2011 — first as CEO of AmeriSource Health Corporation, then of the combined entity after its merger with Bergen Brunswig in 2001. Over fourteen years, he grew the company from approximately $7 billion in annual revenue to $78 billion.

AmerisourceBergen was one of the three largest pharmaceutical distributors in the United States. The business model is simple: manufacturers produce drugs, distributors move them from manufacturers to pharmacies, pharmacies dispense them to patients. Every prescription opioid that reached a pharmacy counter in America traveled through a company like AmerisourceBergen. On the company’s best years under Yost, it ranked in the top ten of the Fortune 500.

He retired on July 1, 2011, at age 63. The company announced his departure with a press release thanking him for “37 years of extraordinary service.” He stepped down from the board the same day. He joined the boards of Bank of America, Marsh & McLennan, and Johnson Controls. He received the Air Force Academy’s Distinguished Graduate Award in 2016 — one of approximately 62 ever conferred in the Academy’s history. A plaza on the Doolittle Campus was dedicated in his honor.

As of 2024, his reported holdings in Cencora — the company formerly known as AmerisourceBergen, which changed its name in August 2023 — are valued at over $568 million.

In October 2013, the Wall Street Journal published a profile of Yost under the headline “CEO Quits to Spend Time With Family — Really.” The article treated his retirement as a heartwarming anomaly — the rare executive who actually meant it when he said he was leaving for his family. The Mullen whistleblower complaint had been sitting sealed in the Eastern District of New York for three years. The opioid epidemic was killing 36,000 Americans a year. The Journal did not mention either.

What Happened Under His Watch

The DEA suspension. On April 24, 2007, the U.S. Drug Enforcement Administration suspended AmerisourceBergen’s Orlando, Florida distribution center’s license to distribute controlled substances. The DEA alleged the facility had failed to maintain effective controls against the diversion of hydrocodone to internet pharmacies — from January 2006 through January 2007, under Yost’s leadership. AmerisourceBergen settled while expressly denying the allegations. The license was reinstated four months later. Yost was not disciplined. He was not investigated. He remained CEO for four more years.

The whistleblower. In 2010 — while Yost was still CEO — Michael Mullen, the former chief operating officer of AmerisourceBergen Specialty Group, filed a sealed qui tam whistleblower complaint in the Eastern District of New York. Mullen alleged that company subsidiaries had operated an unlicensed facility where employees removed cancer drugs from their original manufacturer vials, pooled them into untested containers, and generated millions of dollars in illicit profit from the “overfill.” His amended complaint, later unsealed, identified executives who knew about the scheme — including, the complaint alleged, “the former and current AmerisourceBergen CEOs.”

AmerisourceBergen Specialty Group ultimately pleaded guilty to criminal charges. The combined civil and criminal settlement, announced in 2018 by the Department of Justice as the largest False Claims Act recovery of that year, totaled $885 million. Yost was never charged. He was never named as a defendant. He kept the money.

The emails. During the May 2021 opioid bellwether trial in West Virginia — Cabell County and the city of Huntington versus AmerisourceBergen, Cardinal Health, and McKesson — internal company emails were introduced as evidence for the first time. They had been shielded from congressional investigators. Introduced in open court, they showed Senior Vice President Chris Zimmerman, the executive responsible for enforcing AmerisourceBergen’s legal obligation to halt suspicious opioid deliveries, circulating parody lyrics mocking opioid addicts as “Pillbillies” and forwarding an email with a fake cereal box labeled “OxyContin for Kids.” The emails spanned from 2011 through 2017. Zimmerman apologized on the stand. He said the company culture was “of the highest caliber.” He was not terminated. He was not disciplined. The company put him on the witness stand to testify in its defense at a subsequent trial in Washington State.

The Senate investigation. In July 2018, U.S. Senator Claire McCaskill’s Senate investigation revealed that AmerisourceBergen had shipped approximately 650 million doses of opioids into Missouri alone over six years — yet filed only 224 suspicious order reports with the DEA during that period. For comparison, McKesson shipped the same volume of opioids into Missouri and filed 16,714 suspicious order reports. Cardinal Health shipped half the volume and filed 5,125 reports. McCaskill called the opioid crisis “a failure of basic human morality on the part of many pharmaceutical companies and distributors.”

The Settlements

The bill came due after Yost left. But the conduct that generated it happened while he was in charge.

National opioid settlement (AmerisourceBergen share, 2022) — $6,100,000,000

Mullen whistleblower / drug adulteration (2017–2018) — $885,000,000

Ohio counties opioid settlement (2019) — $260,000,000

Total — $7,245,000,000

The company that Yost built paid $7.2 billion for conduct that occurred, in substantial part, during his fourteen-year tenure. The company changed its name. Yost kept the $568 million.

The Honors

While AmerisourceBergen distributed the pills, R. David Yost was collecting accolades.

In 2016, the United States Air Force Academy named him a Distinguished Graduate — one of approximately 62 in the institution’s entire history, an honor shared with astronauts, combat generals, and Medal of Honor recipients. The Academy dedicated Yost Plaza on the Doolittle Campus in his honor, featuring a seven-foot replica of the graduation ring.

The Air Force Academy’s core values are Integrity First. Service Before Self. Excellence in All We Do.

Veterans die of opioid overdoses at twice the civilian rate. The pills distributed by AmerisourceBergen reached VA hospitals and military communities across the country. The Air Force Academy has not reviewed, revoked, or publicly addressed the Distinguished Graduate Award it conferred upon R. David Yost.

The Question Nobody Has Asked

R. David Yost ran one of the three companies most responsible for the worst drug epidemic in American history. During his fourteen years as CEO, more than 300,000 Americans died of drug overdoses. His company paid $7.2 billion in settlements for conduct during his tenure. He has collected honors and board seats. He has a plaza.

He has never been charged. He has never been fined. He has never been investigated personally. He has never made a public statement about the opioid crisis. No public record exists of any charitable contribution to opioid recovery, treatment, or prevention.

The Sacklers got documentaries and congressional hearings and their names ripped off museum walls. R. David Yost got a plaza. The family that made the pills has become synonymous with the epidemic. The man who shipped them for fourteen years is invisible.

That’s not an accident. Invisibility is its own kind of privilege. It requires no effort when no one is looking.

In October 2013 — two years after Yost retired — the Wall Street Journal ran a profile under the headline “CEO Quits to Spend Time With Family — Really.” The federal complaint alleging he knew about a cancer drug repackaging scheme was not mentioned. The opioid epidemic was not mentioned. The DEA suspension was not mentioned. The paper found a nice man who loved his grandchildren.

Someone is asking now.

Northpoint Research compiles public accountability records on figures whose professional conduct has affected matters of public concern. Every fact in this article is sourced to public records, government documents, SEC filings, court records, and published reporting. The complete record, with sources, is available at rdavidyost.com.

Contact: northpoint.research@proton.me